Adhering to current clinical guidance supports evidence-based assessment, informs decision-making, and helps reduce complications arising from leukemia. Ongoing review of recommendations and guidance enables clinicians to improve evaluation and management, which supports better patient outcomes.
Today, we have a curated selection of clinical guidelines focusing on and related to leukemia. The guidelines featured below were published as recently as last month through February 2019, and feature recommendations on treating acute myeloid leukemia in older adults, immunotherapy for acute leukemia, and more.
Leukemia Guidelines
- Management of Relapsed/Refractory Disease in Adolescents and Young Adults with ALL
- American Society of Hematology (ASH), February 2026
- Treating Newly Diagnosed Acute Myeloid Leukemia in Older Adults
- American Society of Hematology (ASH), November 2025
- Treatment of Chronic Lymphocytic Leukaemia
- British Society for Haematology (BSH), October 2025
- Targeted Therapies in the First-Line and at Relapse of Chronic Lymphocytic Leukaemia
- European Society for Medical Oncology (ESMO), July 2024
- Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia
- Lymphoma Canada (LCA), August 2023
- Frontline Treatment of Chronic Lymphocytic Leukemia
- Lymphoma Canada (LCA), January 2023
- Antifungal Prophylaxis in Adult Patients with Acute Myeloid Leukemia Treated with Novel Targeted Therapies
- European Hematology Association (EHA), May 2022
- Immunotherapy for the Treatment of Acute Leukemia
- Society for Immunotherapy of Cancer (SITC), October 2020
- Initial Diagnostic Workup of Acute Leukemia
- American Society of Hematology (ASH), College of American Pathologists (CAP), February 2019
Check out other clinical guidelines and sign up for alerts to stay informed on the latest published guidelines and insights.
Copyright © 2026 Guideline Central, all rights reserved.